Evidence map›Paper›PMID 36451377›Full record

ArticleMedicine2022

A clinical guideline-based management of type 2 diabetes by ayurvedic practitioners in Nepal: A feasibility cluster randomized controlled trial protocol.

Kaushik Chattopadhyay, Meghnath Dhimal, Shristi Karki, Prerok Regmi, Bihungum Bista, Tuhin Kanti Biswas, Michael Heinrich, Jeemon Panniyammakal, Nikhil Tandon, Jo Leonardi-Bee and 5 more

Abstract readClinical Trial Protocol
In one paragraph

Article in Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kaushik ChattopadhyayLifespan and Population Health Academic Unit, School of Medicine, University of Nottingham, Nottingham, UK.ORCID 0000-0002-3235-8168
Meghnath DhimalNepal Health Research Council, Kathmandu, Nepal.
Shristi KarkiNepal Health Research Council, Kathmandu, Nepal.
Prerok RegmiNepal Health Research Council, Kathmandu, Nepal.
Bihungum BistaNepal Health Research Council, Kathmandu, Nepal.
Tuhin Kanti BiswasDepartment of Kayachikitsa, J B Roy State Ayurvedic Medical College and Hospital, Kolkata, India.
Michael HeinrichCentre for Pharmacognosy and Phytotherapy, School of Pharmacy, University College London, London, UK.
Jeemon PanniyammakalSree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, India.
Nikhil TandonDepartment of Endocrinology, Metabolism and Diabetes, All India Institute of Medical Sciences, New Delhi, India.
Jo Leonardi-BeeLifespan and Population Health Academic Unit, School of Medicine, University of Nottingham, Nottingham, UK.
Sanjay KinraDepartment of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
Sheila Margaret GreenfieldInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Sarah Anne LewisLifespan and Population Health Academic Unit, School of Medicine, University of Nottingham, Nottingham, UK.
Vasudev UpadhyayDepartment of Ayurveda and Alternative Medicine, Ministry of Health and Population, Kathmandu, Nepal.
Pradip GyanwaliNepal Health Research Council, Kathmandu, Nepal.

Funding

Medical Research Council MR/T003537/1Wellcome Trust
6 · The paper itself

Abstract

introductionType 2 diabetes mellitus (T2DM) is a common chronic condition with significant health and socioeconomic consequences. In Nepal, T2DM is a common disease for which people consult ayurvedic (traditional medical system) practitioners and use ayurvedic medicines. Strong concerns remain about the suboptimal T2DM management of many patients by ayurvedic practitioners, and therefore, based on the best available scientific evidence, we have developed a clinical guideline for managing T2DM by ayurvedic practitioners. The research question to be addressed by a definitive cluster randomized controlled trial (RCT) is whether the introduction of a clinical guideline can improve the management of T2DM by ayurvedic practitioners in Nepal as compared to usual ayurvedic management (i.e., without any clinical guideline). In preparation for this future work, this current study aims to determine the feasibility of undertaking the definitive cluster RCT.

methodsThis is a 2-arm, feasibility cluster RCT with a blinded outcome assessment and a qualitative evaluation. The study is conducted in 12 public and private ayurveda centers in and outside the Kathmandu Valley in Nepal (1:1 intervention:control). Eligible participants should be new T2DM adult patients (i.e., treatment naïve) - the glycated hemoglobin level should be 6.5% or above but less than 9%. At least 120 participants (60/group) will be recruited and followed up for 6 months. Important parameters, needed to design the definitive trial, will be estimated, such as the standard deviation of the outcome measure (i.e., glycated hemoglobin level at 6-month follow-up), intraclass correlation coefficient, cluster size, recruitment, the time needed to recruit participants, follow-up, and adherence to the recommended ayurvedic medicine. Semi-structured qualitative interviews will be conducted with around 20 to 30 participants and all the participating ayurvedic practitioners to explore their experiences and perspectives of taking part in the study and of the intervention and a sample of eligible people declining to participate in the study to explore the reasons behind nonparticipation. DISCUSSION: We are now conducting a feasibility cluster RCT in Nepal to determine the feasibility of undertaking the definitive cluster trial. The first participant was recruited on 17 July 2022. If the feasibility is promising (such as recruitment, follow-up, and adherence to the recommended ayurvedic medicine), then the parameters estimated will be used to design the definitive cluster trial. Decisions over whether to modify the protocol will mainly be informed by the qualitative data.

Indexed as

Diabetes Mellitus, Type 2AdultFeasibility StudiesGlycated HemoglobinHumansNepalOutcome Assessment, Health CareRandomized Controlled Trials as TopicGlycated Hemoglobin

Identifiers

PMID36451377
PMCPMC9704971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.